A team from Sweden assessed the risk of hepatic and extrahepatic malignancies in patients with primary sclerosing cholangitis (PSC).
Some 604 Swedish PSC patients, identified between 1970 and 1998, were included in the study.
The risk of hepatic and extrahepatic malignancies in the general population was also assessed.
Follow-up was provided through linkages to the Swedish Cancer and Death registries.
The median time of follow-up was 5.7 years (range 0-27.8).
The researchers found that 79% had concomitant inflammatory bowel disease.
|Increased risk of malignancy in PSC|
| Journal of Hepatology|
The cause of death was cancer in 44% of the patients.
A total of 81 individuals were diagnosed with hepatobiliary malignancies (13%). Of these, 37% were diagnosed less than 1 year after the diagnosis of PSC.
The risk for hepatobiliary malignancy among PSC patients was increased 161-times, compared with that of the general population.
The risks for colorectal carcinoma and for pancreatic carcinoma were increased 10-times and 14-times, respectively.
Author Annika Bergquist, of the Karolinska Institute, Stockholm, Sweden, said on behalf of fellow colleagues, "In this national-based study, including the largest cohort of PSC patients ever presented, the frequency of cholangiocarcinoma is 13%.
"The risk of hepatobiliary carcinoma is constant after the first year after PSC diagnosis with an incidence rate of 1.5% per year."
"These results are suggestive of an increased risk of pancreatic carcinoma in patients with PSC," it was concluded.